Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $95,208.96 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 2,816 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the transaction, the insider now owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. The trade was a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $27.44 on Friday. The stock has a market cap of $3.41 billion, a P/E ratio of -13.52 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock’s fifty day moving average is $31.88 and its 200 day moving average is $33.82. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same period last year, the business earned ($1.17) EPS. Sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. HC Wainwright decreased their target price on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Oppenheimer dropped their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Bank of America reduced their price target on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $25.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. Finally, The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target for the company. in a research note on Tuesday, December 17th. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.94.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently modified their holdings of APLS. Envestnet Asset Management Inc. raised its position in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after purchasing an additional 39,931 shares during the period. JPMorgan Chase & Co. increased its stake in Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares in the last quarter. Profund Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 90.7% in the second quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after acquiring an additional 20,435 shares in the last quarter. Algert Global LLC boosted its stake in shares of Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock worth $4,742,000 after acquiring an additional 71,650 shares during the period. Finally, Edgestream Partners L.P. grew its position in shares of Apellis Pharmaceuticals by 240.4% during the second quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock worth $2,093,000 after purchasing an additional 38,541 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).